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Abstract 
 
The CRISPR/Cas9 system has emerged as an important tool for a wide variety of genome 
engineering applications, including reverse genetic screens. Previously, we described the 
implementation of the CRISPR/Cas9 system to induce tissue-specific mutations at targeted 
locations in the genome of the sea squirt Ciona (STOLFI et al. 2014). In the present study, we 
designed 83 single guide RNA (sgRNA) vectors targeting 23 genes expressed in the 
cardiopharyngeal progenitors and surrounding tissues in the Ciona embryo and measured their 
mutagenesis efficacy rates by massively parallel indel detection at the targeted loci using high-
throughput sequencing. We show that the combined activity of two highly active sgRNAs allows 
us to generate large (>3 kbp) deletions of intervening genomic DNA in somatic cells of 
electroporated embryos, permitting tissue-specific gene knockouts. Additionally, we employed 
L1-regularized regression modeling to develop an optimal sgRNA design algorithm (TuniCUT), 
based on correlations between target sequence features and mutagenesis rates. Using this 
algorithm, we have predicted mutagenesis rates for sgRNAs targeting all 4,853,589 sites in the 
Ciona genome, which we have compiled into a “CRISPR/Cas9-induced Ciona Knock-Out” 
(Ci2KO) sgRNA sequence library. Finally, we describe a new method for the assembly of 
sgRNA expression cassettes using a simple one-step overlap PCR (OSO-PCR) protocol. These 
cassettes can be electroporated directly into Ciona embryos as unpurified PCR products to drive 
sgRNA expression, bypassing the need for time-consuming cloning and plasmid DNA 
preparations. We anticipate that this method will be used in combination with genome-wide 
sgRNA predictions to systematically investigate tissue-specific gene functions in Ciona. 
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Introduction 
A platform for targeted mutagenesis has been recently developed based on the prokaryotic 
immune response system known as CRISPR/Cas (Clustered Regularly Interspaced Short 
Palindromic Repeats/CRISPR-Associated) (BARRANGOU et al. 2007). In its most common 
derivation for genome engineering applications, the system makes use of a short RNA sequence, 
known as a single guide RNA (sgRNA) to guide the Cas9 nuclease of Streptococcus pyogenes to 
a specific target DNA sequence. (JINEK et al. 2012; CONG et al. 2013; JINEK et al. 2013; MALI et 
al. 2013). Although initial Cas9 binding requires a Protospacer Adjacent Motif (PAM) sequence 
of “NGG”, the high specificity of this system is accounted for by Watson-Crick base pairing 
between the 5’ end of the sgRNA and an 17-20bp “protospacer” sequence immediately adjacent 
to the PAM (FU et al. 2014). Upon sgRNA-guided binding to the intended target, Cas9 generates 
a double stranded break (DSB) within the protospacer sequence. Imperfect repair of these DSBs 
by non-homologous end joining (NHEJ) often results in short insertions or deletions (indels) that 
may disrupt the function of the targeted sequence. Numerous reports have confirmed the high 
efficiency of CRISPR/Cas9 for genome editing purposes (DICKINSON et al. 2013; HWANG et al. 
2013; WANG et al. 2013a; SHALEM et al. 2014; GANTZ AND BIER 2015). 
 
The tunicate Ciona has emerged as a model organism for the study of chordate-specific 
developmental processes (SATOH 2013). The CRISPR/Cas9 system was recently adapted to 
induce site-specific DSBs in the Ciona genome (SASAKI et al. 2014). Using electroporation to 
transiently transfect Ciona embryos with plasmids encoding CRISPR/Cas9 components, we were 
able to generate clonal populations of somatic cells carrying loss-of-function mutations of Ebf, a 
transcription-factor-coding gene required for muscle and neuron development, in F0-generation 
embryos (STOLFI et al. 2014). By using developmentally regulated cis-regulatory elements to 
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drive expression of Cas9 in specific cell lineages or tissue types, we were thus able to control the 
disruption of Ebf function with spatiotemporal precision. 
 
We sought to expand the strategy to target more genes, with the ultimate goal of building a 
genome-wide library of sgRNAs for systematic genetic loss-of-function assays. However, 
CRISPR/Cas9-based genome engineering is still in its infancy, and few guidelines exist for the 
rational design of highly active sgRNAs, which are critical for rapid gene disruption in F0. 
Individual studies have revealed certain protospacer-targeting sequence features that correlate 
with high sgRNA expression and/or activity in CRISPR/Cas9-mediated DNA cleavage (DOENCH 
et al. 2014; GAGNON et al. 2014; REN et al. 2014; CHARI et al. 2015; MORENO-MATEOS et al. 
2015), but these have been performed in different organisms, using a variety of sgRNA and Cas9 
delivery methods. 
 
Given the uncertainty regarding how sgRNA design principles gleaned from experiments in 
other species might be applicable to CRISPR/Cas9 efficacy in Ciona, we tested a collection of 
sgRNAs using our own modified tools for tissue-specific CRISPR/Cas9-mediated mutagenesis in 
Ciona embryos. We describe here the construction and validation of this collection using high-
throughput sequencing of PCR-amplified target sequences. This dataset allowed us to develop a 
pipeline for machine-learning-optimized design and efficient assembly of sgRNA expression 
constructs for use in Ciona. Using these methods, we have pre-emptively designed and predicted 
the mutagenesis efficacy rates of sgRNAs targeting all 4,853,589 viable Cas9 target sites 
(4,249,756 of them unique) identified in the entire Ciona genome. This “CRISPR/Cas9-Induced 
Ciona Knock-Out” (Ci2KO) sgRNA database should facilitate the widespread use of 
CRISPR/Cas9 by the Ciona research community. 
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Results 
High-Throughput sequencing to estimate sgRNA-specific mutagenesis rates 
Previous studies using CRISPR/Cas9-based mutagenesis in Ciona suggested that individual 
sgRNAs define the level of endonuclease activity of Cas9/sgRNA complexes, therefore varying 
mutagenesis rates at distinct target sites (SASAKI et al. 2014; STOLFI et al. 2014). In order to test 
a larger number of sgRNAs and search for parameters that may influence mutagenesis efficacy, 
we constructed a library of 83 sgRNA expression plasmids targeting a set of 23 genes (Table 1). 
The majority of these genes are transcription factors and signaling molecules of potential interest 
in the study of cardiopharyngeal mesoderm development. The cardiopharyngeal mesoderm of 
Ciona, also known as the Trunk Ventral Cells (TVCs), are multipotent cells that invariantly give 
rise to the heart and pharyngeal muscles of the adult (HIRANO AND NISHIDA 1997; STOLFI et al. 
2010; RAZY-KRAJKA et al. 2014), thus sharing a common ontogenetic motif with the potentially 
homologous cardiopharyngeal mesoderm of vertebrates (WANG et al. 2013b; DIOGO et al. 2015). 
 
We followed a high-throughput-sequencing-based approach to quantify the efficacy of each 
sgRNA (Figure 1a). The 83 sgRNA plasmids were individually co-electroporated with 
Eef1a1>nls::Cas9::nls plasmid into pools of Ciona zygotes, which were then grown at 18°C for 
16 hours post-fertilization (hpf; embryonic stage 25)(HOTTA et al. 2007). Targeted sequences 
were individually PCR-amplified from each pool of embryos, as well as from “negative control” 
embryos (electroporated with Eef1a1>nls::Cas9::nls and “U6>Negative Control” sgRNA 
vector) grown in parallel to each batch of electroporated embryos. Agarose gel-selected and 
purified amplicons (varying from 108 to 350 bp in length) were pooled in a series of barcoded  
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Table 1. Genes targeted for CRISPR/Cas9-mediated mutagenesis 
The 23 genes targeted in the initial screen, each identified here by official gene symbol, aliases, and KyotoHoya 
identifier. 
 
# Gene Symbol Aliases 2012 KyotoHoya ID 
1 Bmp2/4 Bone morphogenetic protein 2/4 KH.C4.125 
2 Ddr Discoidin Domain Receptor Tyrosine Kinase 1/2 KH.C9.371 
3 Ebf Collier/Olf/EBF; COE KH.L24.10 
4 Eph.a Ephrin type-A receptor.a; Eph1 KH.C1.404 
5 Ets.b Ets/Pointed2 KH.C11.10 
6 Fgf4/6 Fibroblast growth factor 4/6; FGF, unassigned 1 KH.C1.697 
7 Fgf8/17/18 Fibroblast growth factor 8/17/18 KH.C5.5 
8 Fgfr Fibroblast growth factor receptor KH.S742.2 
9 Foxf FoxF KH.C3.170 
10 Foxg-r Foxg-related; Orphan Fox-4; Ci-ZF248 KH.C5.74 
11 Fzd5/8 Frizzled5/8 KH.C9.260 
12 Gata4/5/6 GATA-a KH.L20.1 
13 Hand Heart And Neural Crest Derivatives Expressed 1/2 KH.C14.604 
14 Hand-r Hand-related; Hand-like; NoTrlc KH.C1.1116 
15 Htr7-r 5-Hydroxytryptamine Receptor 7-related KH.S555.1 
16 Isl Islet1/2 KH.L152.2 
17 Lef1 Lef/TCF KH.C6.71 
18 Mrf Muscle regulatory factor; MyoD KH.C14.307 
19 Neurog Neurogenin; Ngn KH.C6.129 
20 Nk4 Nkx2-5; Tinman KH.C8.482 
21 Rhod/f RhoD/F; Rif KH.C1.129 
22 Tle.b Groucho2 KH.L96.50 
23 Tll Tolloid-like; Tolloid KH.C12.156 
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 Figure 1. Next-Generation Sequencing approach to validating sgRNAs for use in Ciona embryos 
a) Schematic for next-generation sequencing approach to measuring mutagenesis efficacies of sgRNAs expressed in 
F0 Ciona embryos. See results and materials and methods for details. b) Representative view in IGV browser of 
coverage (grey areas) of sequencing reads aligned to the reference genome. “Dip” in coverage of reads from 
embryos co-electroporated with Eef1a1>Cas9 and U6>Htr7-r.1 sgRNA vector indicates CRISPR/Cas9-induced 
indels around the sgRNA target site, in the 2nd exon of the Htr7-related (Htr7-r) gene. Colored bars in coverage 
indicate single-nucleotide polymorphisms/mismatches relative to reference genome. c) Diagram representing a stack 
of reads bearing indels of various types and sizes, aligned to exact target sequence of Htr7-r.1 sgRNA. d) 
Distribution of mutagenesis efficacy rates measured for each sgRNA, ordered from lowest (0%) to highest 
(59.63%). e) Box-and-whisker plots showing the size distribution of insertions and deletions caused by Ebf.3 or 
Lef1.2 sgRNAs. Dashed box with asterisk indicates outliers.  
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“targeted” and “negative control” Illumina sequencing libraries and sequenced using the Illumina 
MiSeq platform. 
 
Alignment of the resulting reads to the reference genome sequence (SATOU et al. 2008) revealed 
that targeted sites were represented on average by 16,204 reads, with a median of 3,899 reads 
each (Table 2; note that we excluded the Bmp2/4.1 sgRNA from further analyses because only 
two reads mapped to its target sequence). The ability of each sgRNA to guide Cas9 to induce 
DSBs at its intended target was detected by the presence of insertions and deletions (indels) 
within the targeted protospacer + PAM. The simple ratio of [indels]/[total reads] represents the 
mutagenesis efficacy of the sgRNA (Figure 1b-d, Table 2, Supplementary Table 1). For 
simplicity, we did not count single nucleotide polymorphisms (SNPs), even though a fraction of 
them may result from NHEJ-repair of a DSB event. Our data indicated that all sgRNAs (with the 
exception of Neurog.2) were able to induce DSBs, with estimated efficacies varying from 0.05% 
(Ebf.4) to 59.63% (Htr7-r.2). 
 
This conservative approach most likely underestimates the actual mutagenesis rates. First, we 
excluded SNPs potentially resulting from imperfect DSB repair. Second, but more importantly, 
amplicons from transfected cells are always diluted by wild-type sequences from untransfected 
cells in the same sample, due to mosaic incorporation of sgRNA and Cas9 plasmids. Indeed, we 
previously observed an enrichment for mutated sequences amplified from reporter transgene-
expressing cells isolated by magnetic-activated cell sorting (representing the transfected 
population of cells) relative to unsorted cells (representing mixed transfected and untransfected 
cells) (STOLFI et al. 2014). In that particular example, the estimated mutagenesis efficacy 
induced by the Ebf.3 sgRNA was 66% in sorted sample versus 45% in mixed sample. This  
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Table 2. All sgRNAs and their mutagenesis efficacy rates (Mut%) assayed by next-
generation sequencing 
Protospacer and PAM sequences, number of reads sequenced and indels detected for each sgRNA in this study. 
Ebf.3 was tested either as a plasmid or unpurified traditional PCR and OSO-PCR cassettes (see text for details). 
 
gRNA Protospacer (N19) + PAM Reads Indels Mut% 
Bmp2/4.1 CTGCATAATACGCGGGACCTGG 2 0 0.00* 
Bmp2/4.2 CTAGAAGTTATCACCACGAAGG 8032 2001 24.91 
Bmp2/4.3 ATGTGGTTGCTCGGCATCCCGG 4821 620 12.86 
Bmp2/4.4 GAGCTTCTCCTGCATCGAGAGG 20319 7686 37.83 
Ddr.1 CTACAGCACAAATAGATACWGG 1146 44 3.84 
Ddr.2 CAATGCTATCCATTGGGGCAGG 2597 1101 42.40 
Ddr.3 GAGCGTCCGCAGTTGTCGCTGG 270 9 3.33 
Ddr.4 CATCCACTGGTGCAGGGGTTGG 854 401 46.96 
Ddr.5 TGAGCCTTATGTCTCTGCATGG 2118 695 32.81 
Ebf.1 TACGACAGACAAGGGCAGCTGG 923 227 24.59 
Ebf.2 GCATCCATCCTCTCACTGCCGG 825 41 4.97 
Ebf.3 CTGAGGGTTGGACAACAGGWGG 923 344 37.27 
Ebf.3 (PCR) CTGAGGGTTGGACAACAGGWGG 346167 104397 30.16 
Ebf.3 (OSO-PCR) CTGAGGGTTGGACAACAGGWGG 9264 3174 34.26 
Ebf.4 TTGGAGAAAATTTCTTTGACGG 10184 5 0.05 
Eph.a.1 ATTCACGATAAGGTAAGACGGG 1528 354 23.17 
Eph.a.2 GGCTGCAATCGTATCAACCTGG 915 320 34.97 
Eph.a.3 AATTGGGGACACATTGTCCTGG 3703 1374 37.11 
Ets.b.1 ATATCTCGCCCACAAATGGAGG 1740 162 9.31 
Ets.b.2 ATCTTGATAGGTTGCAGTCAGG 23999 1373 5.72 
Ets.b.3 GAGTGGTCCAATCCAACTGTGG 975 373 38.30 
Ets.b.4 CTTACCTTGCTACTTCATCTGG 916 1 0.12 
Ffg4/6.1 CCCGCAATTCAGTACCTGTCGG 6540 2453 37.51 
Ffg4/6.2 AGTCTTTATTCCGTAGCTCGGG 5014 982 19.59 
Ffg4/6.3 CATCTCGGTGGACAATATGTGG 57606 11894 20.65 
Ffg4/6.4 TGTTCATTTAGGCTTACCATGG 8182 838 10.24 
Fgf8/17/18.1  CTCGGAGACATAGCCAGCGGGG 3899 1554 39.86 
Fgf8/17/18.2  GGACGACTAGTTGGAAAGGTGG 6193 1933 31.21 
Ffgr.1 CAACACACGTCTTACCTTCTGG 1209 292 24.15 
Ffgr.2 CAAACGGAGCACCAAAAAGTGG 1744 530 30.39 
Ffgr.3 TTGAACTGCACATCTAAACTGG 1459 34 2.33 
Ffgr.4 TACATCCAGTTCGTAAGTATGG 6117 1486 24.29 
Foxf.1 CCATTCGCTGCGACCGCTGCGG 2420 703 29.05 
Foxf.2 ACTCTGCCCATCCCGCCAAAGG 27427 4830 17.61 
Foxf.3 ACAGCCACCTCGCTTATGAAGG 5147 1477 28.70 
Foxf.4 GTATATATAAGGGGCTCAGCGG 5820 2257 38.78 
Foxg-r.1 AGAGAGGTCCCAATACAAAAGG 3559 67 1.87 
Foxg-r.2 GTTGAGACTGAGATTGTGACGG 5472 2087 38.14 
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Foxg-r.3 ATTGGACCATGACGAGAGAGGG 4005 407 10.16 
Foxg-r.4 TCAAAAGGAGACGAAGACGAGG 36132 124 0.34 
Fzd5/8.1 TGCGAATGCACTTACCGACTGG 3624 547 15.09 
Fzd5/8.2 CTTAGTCAAAGGGCCGAATTGG 3948 941 23.83 
Fzd5/8.3 ACACCCCGATCTGTATACCTGG 33293 9853 29.59 
Fzd5/8.4 GGTCATTCTGTCACTGACTTGG 459 85 18.52 
Gata4/5/6.1 CTACGGTAGGGGTAGTAGTAGG 3475 1502 43.22 
Gata4/5/6.2 GTAACGGTTGTGCTACAGTTGG 2621 360 13.74 
Gata4/5/6.3 AGAAGTCCGGACGGAAACCCGG 30165 12270 40.68 
Gata4/5/6.4 CGTAGAGGCTGACGTCACGAGG 1686 597 35.41 
Hand.1 TTTGTATCCGACGGTACGTTGG 183 65 35.52 
Hand.2 CCCGTACAGTCGCCGGTATCGG 20560 6369 30.98 
Hand.3 GGGTTCCGCGCCGACTTAAAGG 7507 392 5.22 
Hand.4 TACTTCGGTGTAAGTCAATTGG 2224 513 23.07 
Hand-r.1 GCAACCGAAAACCCACACATGG 5118 628 12.27 
Hand-r.2 AACATTGGGAGGGTAGCGGGGG 37245 8178 21.96 
Hand-r.3 GAACCCTTGTTTGATAACTTGG 3602 317 8.80 
Hand-r.4 CATCGTTAATTCTACTCTGYGG 7760 58 0.75 
Htr7-r.1 AACTCCTGAGTTCTTGAGACGG 1812 1053 58.11 
Htr7-r.2 TGATCTGGCAATCACAGCATGG 20142 12011 59.63 
Htr7-r.3 ACACAGAAAGACACTGGGGTGG 1048 461 43.99 
Htr7-r.4 AAGCAAAGGGGGACTCCCTGGG 1023 367 35.87 
Islet.2  GATGCGGCAGGGGTCTGTAAGG 2390 1050 43.93  
Lef1.1 AGAATGCCTCAGTTAAACTCGG 3547 1067 30.08 
Lef1.2 CGTAAGATTGTCGCCTGTGTGG 1588 692 43.58 
Mrf.1 ATGGGGTTTGTGGCGTAACTGG 2163 335 15.49 
Mrf.2 GACGAACTGAAGAGATGCGTGG 23595 7750 32.85 
Mrf.3 TAGTGTTGCCGCCCTCCGTCGG 5544 1808 32.61 
Mrf.4 CTTAAGGGCGTCGTACGCTTGG 36222 1902 5.25 
Neurog.1 CTTACCATTACGTCTTGTGAGG 2456 579 23.57 
Neurog.2 TTAACTTGTTAATTGTCACAGG 5585 0 0.00  
Nk4.1 GGAAGTGATTCATCCGTACAGG 5088 719 14.13 
Nk4.2 AATCAGTTACTCAAGTCACGGG 41237 18969 46.00 
Nk4.3 AACCAGATCTTGACCTGGGTGG 3125 1181 37.79 
Nk4.4 CAAGACAAAACCTTAGAGCTGG 37168 5134 13.81 
Rhod/f.1 TAGTTGGGGATGGTGGATGCGG 2882 1682 58.36 
Rhod/f.2 TCAAAGGTGTACACGCCCACGG 3755 841 22.40 
Rhod/f.3 TAACATTGTGGGATACGGCGGG 23845 9707 40.71 
Rhod/f.4 CCAGAACGTAGAAATCCGATGG 625 22 3.52 
Tle.b.1 TAGACTTACCTCTTGTGACAGG 5808 1570 27.03 
Tle.b.2 ACCCGACAGCTCCCATACCYGG 3933 1035 26.32 
Tle.b.3 GGAGGGAGTCCTGGAGGGTGGG 30004 11731 39.10 
Tle.b.4 TTCCCTCCTCCTCCGCAGCCGG 288073 20041 6.96 
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Tll.1 CACCGATTGGGGACCGGGTTGG 546 150 27.47 
Tll.2 CGTATTGGTACGGTTGCCTTGG 7606 180 2.37 
Tll.3 AGCAAGGGCGGGTCGCAGAAGG 4367 97 2.22 
Tll.4 GAATAGACACAGGCGACTTCGG 3243 347 10.70 
 
suggests the actual efficacies of some sgRNAs may be up to 1.5-fold higher than their measured 
rates. 
 
Analysis of unique indels generated by the activity of two different sgRNAs, Ebf.3 and Lef1.2, 
indicated a bias towards deletions rather than insertions, at a ratio of roughly 2:1 
deletions;insertions (Figure 1d). However, these two sgRNAs generated different distributions 
of indel lengths, indicating indel position and size may depend on locus-specific repair 
dynamics. 
 
Numerous studies have reported the potential off-target effects of CRISPR/Cas9 in different 
model systems (FU et al. 2013; HSU et al. 2013; PATTANAYAK et al. 2013; CHO et al. 2014). For 
this study, we were able to mostly select highly specific sgRNAs, owing to the low frequency of 
predicted off-target sequences in the small, A/T-rich Ciona genome (see Discussion for details). 
To test the assumption that off-target DSBs are unlikely for partial sgRNA seed-sequence 
matches, we analyzed the mutagenesis rates at two potential off-target sites that matched the 
protospacer at the 10 and 8 most PAM-proximal positions of the Ebf.3 and Fgf4/6.1 sgRNAs, 
respectively. We did not detect any mutations in 5,570 and 6,690 reads mapped to the two loci, 
respectively, suggesting high specificity of the sgRNA:Cas9 complex to induce DSBs only at 
sites of more extensive sequence match in developing Ciona embryos.  
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Identifying sequence features correlated with sgRNA efficacy 
Recent studies in different model organisms have examined the nucleotide preferences amongst 
sgRNAs inducing high or low rates of mutagenesis (DOENCH et al. 2014; GAGNON et al. 2014; 
REN et al. 2014; CHARI et al. 2015; MORENO-MATEOS et al. 2015). However, Ciona rearing 
conditions differ from those of other model systems, being a marine invertebrate that develops 
optimally at 13-20°C. Moreover, most CRISPR/Cas9-based experiments in Ciona rely on in vivo 
transcription of sgRNAs built with a modified “F+E” backbone (CHEN et al. 2013) by a Ciona-
specific U6 small RNA promoter transcribed by RNA Polymerase III (PolIII)(NISHIYAMA AND 
FUJIWARA 2008).  Therefore, in order to identify potential sequence features in target sequences 
that might contribute towards a higher or lower mutagenesis rate specifically in Ciona embryos, 
we analyzed our dataset for potential correlations between target sequence composition and 
sgRNA-specific mutagenesis rate.  
 
We hypothesized that, if mutagenesis efficacy can be predicted by nucleotide composition at 
defined positions in the protospacer and flanking sequences, then comparing the target sequences 
of the most and least active sgRNAs in our dataset should reveal features that affect 
CRISPR/Cas9 efficacy in Ciona. To that effect, we performed nucleotide enrichment analyses 
for the top and bottom 25% sgRNAs ranked by measured mutagenesis efficacy (Figure 2a,b, 
Supplementary Figure 1)(SCHNEIDER AND STEPHENS 1990; CROOKS et al. 2004). For the top 
25% sgRNAs, guanine was overrepresented in the PAM-proximal region, while the ambiguous 
nucleotide of the PAM (‘N’ in ‘NGG’) was enriched for cytosine. We also observed an overall 
depletion of thymine in the protospacer sequence for the top 25% sgRNAs, likely due to 
premature termination of PolIII-driven transcription as previously demonstrated (WU et al. 
2014). Among the bottom 25% sgRNAs, we observed a higher representation of cytosine at 
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nucleotide 20 of the protospacer (Figure 2b, Supplementary Figure 1). All these observations 
are consistent with the inferences drawn from previous studies, suggesting that certain sgRNA 
and target sequence features that influence Cas9:sgRNA-mediated mutagenesis rates are 
consistent across different metazoans (GAGNON et al. 2014; CHARI et al. 2015; MORENO-
MATEOS et al. 2015). 
 
Machine learning reveals rational design principles for highly active sgRNAs 
CRISPRScan is an online tool for rational sgRNA design, based on large-scale sgRNA validation 
in zebrafish embryos (MORENO-MATEOS et al. 2015).  However, we reasoned that fundamental 
differences in sgRNA backbone and delivery method between CRISPR/Cas9 experiments in 
zebrafish and Ciona would necessitate a novel algorithm to identify and construct sgRNAs with 
high activity specifically in Ciona. 
 
 In order to uncover additional sequence-based determinants of sgRNA activity, especially 
synergistic effects of nucleotide features at disjointed positions in and around the targeted 
sequence, we used a linear regression-based approach and trained an L1 regularized LASSO 
(Least Absolute Shrinkage and SelectiOn) regression model to identify which single- and dual 
nucleotide features of the protospacer, PAM, and flanking sequences affected mutagenesis 
efficacy the most (Supplementary Table 3,4)(TIBSHIRANI 1996). We used L1 regularization in 
our model to efficiently perform feature selection in a sparse feature space. We identified 
sequence feature effects by fitting a unified training set comprising the top and bottom 25% 
sgRNAs. This regression model, which we named “TuniCUT”, was then used to predict the 
efficacy rates of the remaining sgRNAs that were left out of the training set. TuniCUT 
predictions were plotted against the actual measured efficacy rates to visualize the accuracy of  
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 Figure 2. Correlations between sgRNA sequence composition and mutagenesis efficacy 
a) Log-odds scores depicting the frequency of occurrence for nucleotides in the top 25% most effective sgRNAs, at 
all positions of the protospacer, PAM, and flanking regions. Position “1” of the protospacer has been omitted from the 
analysis, due to this always being “G” for PolIII-dependent transcription of U6-promoter-based vectors. Likewise, the 
“GG” of the PAM has also been omitted, as this sequence is invariant in all targeted sites. b) WebLogos representing 
the nucleotide composition at each variable position of the protospacer (nt 2-20, X axis), in top 25% and bottom 25% 
performing sgRNAs. c) All sgRNAs in this study plotted by their mutagenesis efficacy rates (Y axis). The top 25% 
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and bottom 25% sgRNAs constituted the training set (blue dots) for the TuniCUT prediction model. TuniCUT was 
then used to predict the efficacies of the remaining sgRNAs (magenta dots). d) The performance of TuniCUT was 
tested by plotting the Area Under the Curve of the Receiver Operator Characteristic (AUC-ROC). The area was 
calculated based on the discrimination ability of a classifier which was fitted to the training data using key parameters 
identified by Lasso regression. 
 
our model (Figure 2c). Based on variable uptake of plasmid DNA by electroporation (ZELLER et 
al. 2006; STOLFI et al. 2014), we accommodated an arbitrary error of ±10%.  
 
In a previous study, highly penetrant, tissue-specific loss-of-function phenotypes in F0 embryos 
were elicited using Ebf.3 sgRNA, which had a measured mutagenesis efficacy of 37% (STOLFI et 
al. 2014). We thus reasoned that an sgRNA with an efficacy of ~25% would be acceptable for 
loss-of-function assays. Based on this rationale, we defined a threshold of 25%, which was close 
to the median value of measured mutagenesis rates (26%), and the training set was binned, with 
values 0 and 1 representing sgRNAs with an estimated efficacy of less than 25% (“bad”) and 
greater than or equal to 25% (“good”), respectively.  We fit a logistic regression classifier using 
this transformed training set, and used an L2 regularization to minimize prediction error (NG 
2004).  Once the model was fitted to the data, we tested the performance of this prediction model 
by plotting sensitivity (True Positive Rate) versus specificity (False Positive Rate) as the 
Receiver Operator Characteristic (ROC) curve (HANLEY AND MCNEIL 1982). The area under this 
curve (AUC) yielded a moderately predictive value of 0.7 (Figure 2d). In other words, our 
model has a 70% probability of discriminating between a “good” (efficacy  25%) and a “bad” 
(efficacy < 25%) sgRNA, which represents a ~40% increase in the likelihood of identifying 
efficient sgRNAs as compared to chance. 
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Multiplexed targeting with CRISPR/Cas9 generates large deletions in the Ciona genome 
Large deletions of up to 23 kb of intervening DNA resulting from NHEJ between two 
CRISPR/Cas9-induced DSBs have been reported in Ciona (ABDUL-WAJID et al. 2015). For 
functional analyses of protein-coding genes, such deletions would more likely produce null 
mutations than small deletions resulting from the action of lone sgRNAs. To test whether we 
could cause tissue-specific, homozygous, large deletions in F0 embryos, we targeted the 
forkhead/winged helix transcription-factor-encoding gene Foxf (Figure 3a), which contributes to 
TVC migration in Ciona (BEH et al. 2007). We co-electroporated Eef1a1>nls::Cas9::nls with 
sgRNA vectors Foxf.4 and Foxf.2 (with induced mutagenesis rates of 39 and 18%, respectively; 
Table 2, Figure 3). We extracted genomic DNA from electroporated embryos and PCR-
amplified the sequence spanning both target sites. We obtained a specific ~300 bp PCR product 
corresponding to the amplified region missing the ~2.1 kbp of intervening sequence between the 
two target sites. Cloning the deletion band and sequencing individual clones confirmed that the 
shorter PCR product corresponds to a deletion of most of the Foxf first exon and 5’ cis-
regulatory sequences (BEH et al. 2007). We did not detect this deletion using genomic DNA 
extracted from embryos electroporated with either sgRNA alone. Similar deletion PCR products 
were observed, cloned, and sequenced for other genes including Nk4, Fgfr, Mrf, Htr7-related, 
Bmp2/4, and Hand, using pairs of highly mutagenic sgRNAs (Supplementary Figure 2). The 
largest deletion recorded was ~3.6 kbp, with sgRNAs Nk4.2 (46% efficacy) and Nk4.3 (38% 
efficacy), entirely removing the sole intron of Nk4 and small portions of the flanking exons.  
 
Foxf is expressed in TVCs and head epidermis, the latter of which is derived exclusively from 
the animal pole (NISHIDA 1987; IMAI et al. 2004; PASINI et al. 2006; BEH et al. 2007). Because  
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 Figure 3. Combinatorial targeting of Foxf results in large deletions 
a) Diagram of Foxf locus, showing positions targeted by Foxf.4 and Foxf.2 sgRNAs. Foxf.4 targets a non-coding, 
cis-regulatory sequence 881 base pairs (bp) upstream of the transcription start site of Foxf. Foxf.2 targets a coding 
sequence in exon 1 of Foxf. The distance between the target sites is 2132 bp, and encompasses most of exon 1, the 
core promoter, and cis-regulatory modules that drive Foxf expression in the head epidermis and trunk ventral cells 
(TVCs) (BEH et al. 2007). Blue arrows indicate primers used to amplify the region between the target sites. In wild-
type embryos, the resulting PCR product is ~2.4 kilobase pairs (kbp). b) Alignment of cloned PCR products 
amplified using the primers indicated in (a), from wild-type (wt) embryos, and from embryos electroporated with 25 
μg EF1α>nls::Cas9::nls and 50 μg each of U6>Foxf.2 and U6>Foxf.4. Colonies 03, 04, and 06 shown containing 
large deletions between the approximate sites targeted by the two sgRNAs, indicating non-homologous end-joining 
(NHEJ) repair from two separate double stranded break events as a result of combinatorial action of Foxf.2 and 
Foxf.4 sgRNAs. c) In situ hybridization for Foxf (green) showing strong expression throughout the head epidermis 
in embryos electroporated with 10 μg Fog>H2B::mCherry (red), 50 μg Fog>nls::Cas9::nls and 45 μg of U6>Ebf.3. 
Foxf expression is essentially wild-type, as Ebf function is not required for activation of Foxf in the epidermis. d) In 
situ hybridization for Foxf (green) showing patchy expression in the head epidermis of embryos electroporated with 
10 μg Fog>H2B::mCherry (red), 50 μg Fog>nls::Cas9::nls and 45 μg each of U6>Foxf.2 and U6>Foxf.4. Loss of 
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in situ signal in some transfected head epidermis cells indicates loss of Foxf activation, presumably through deletion 
of all or part of the upstream cis-regulatory sequences by CRISPR/Cas9. Scale bars = 25 μm. 
 
the ~2.1 kbp deletion introduced in the Foxf locus excised the epidermal enhancer and basal 
promoter (BEH et al. 2007), we sought to examine the effects of these large deletions on Foxf 
transcription. We used the cis-regulatory sequences from Zfpm (also known as Friend of GATA, 
or Fog, and referred to as such from here onwards) to drive Cas9 expression in early animal pole 
blastomeres (ROTHBÄCHER et al. 2007). We electroporated Fog>nls::Cas9::nls together with 
Foxf.2 and Foxf.4 sgRNA vectors and Fog>H2B::mCherry, and raised embryos at 18°C for 9.5 
hpf (early tailbud, embryonic stage 20). We performed whole mount mRNA in situ hybridization 
to monitor Foxf expression, expecting it to be silenced in the epidermis by tissue-specific 
CRISPR/Cas9-induced homozygous deletions of the Foxf cis-regulatory sequences (Figure 3a). 
Indeed, we observed patches of transfected head epidermal cells (marked by H2B::mCherry) in 
which Foxf expression was reduced or eliminated (Figure 3d). This was in contrast to the 
uniform, high levels of Foxf expression observed in “control” embryos electroporated with Ebf.3 
sgRNA (Ebf is unlikely to be involved in Foxf regulation in the epidermis where it is not 
expressed, Figure 3c). Taken together, these results indicate that, by co-electroporating two or 
more sgRNAs targeting neighboring sequences, one can routinely generate homozygous, large 
deletions in the Ciona genome in a tissue-specific manner. 
 
Rapid generation of sgRNA expression cassettes ready for embryo transfection 
CRISPR/Cas9 is an efficient and attractive system for targeted mutagenesis in Ciona, but cloning 
individual sgRNA vectors is a labor-intensive, rate-limiting step. To further expedite  
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Figure 4. One-step Overlap Polymerase Chain Reaction (OSO-PCR) for the high-throughput 
construction of sgRNA expression cassette libraries 
a) Diagram of OSO-PCR for amplification of U6>sgRNA expression cassettes in which the target-specific sequence 
of each (red) is encoded in complementary overhangs attached to universal primers. 1:10 dilution of these primers 
ensures that the overlap product, the entire U6>sgRNA cassette, is preferentially amplified (see methods for details). 
b) Agarose gel electrophoresis showing products of four different U6>sgRNA OSO-PCRs. The desired product is 
~1.2 kilobase pairs (kbp) long. 2logL = NEB 2-Log DNA ladder. c) Detailed diagram of how the overlap primers 
form a target-specific bridge that fuses universal U6 promoter and sgRNA scaffold sequences. d) Larvae co-
electroporated with Sox1/2/3>nls::Cas9::nls, Islet>eGFP, and either 25 µl (~2.5 µg) unpurified 
U6>NegativeControl  PCR (top panel), 25 µl (~2.5 µg) unpurified U6>Ebf.3 PCR (middle panel), or 25 µg 
U6>Ebf.3 plasmid (bottom panel). Islet>eGFP reporter plasmid is normally expressed in the A10.57 motor neuron 
(“Isl+ MN”, green), which is dependent on Ebf function. Islet>eGFP was expressed in MNs in 75 of 100 embryos. 
In embryos electroporated with unpurified U6>Ebf.3 PCR products or U6>Ebf.3 plasmid, only 16 of 100 and 17 of 
100 embryos, respectively, had Islet>eGFP expression in MNs. This indicates similar loss of Ebf function in vivo by 
either unpurified PCR or purified plasmid sgRNA delivery method.  
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CRISPR/Cas9 experiments, we adapted a one-step overlap PCR (OSO-PCR) protocol to generate 
U6 promoter>sgRNA expression “cassettes” for direct electroporation without purification 
(Figure 4a-c, Supplementary Figure 3, see Materials and Methods and Supplementary 
Protocol for details). We tested the efficacy of sgRNAs expressed from these unpurified PCR 
products, by generating such expression cassettes for the validated Ebf.3 sgRNA (Table 
2)(STOLFI et al. 2014). We electroporated Eef1a1>nls::Cas9::nls and 25 µl (corresponding to 
~2.5 µg, see Materials and Methods and Supplementary Figure 4) of unpurified, U6>Ebf.3 
sgRNA OSO-PCR or U6>Ebf.3 sgRNA traditional PCR products (total electroporation volume: 
700 µl). Next-generation sequencing of the targeted Ebf.3 site revealed mutagenesis rates similar 
to those obtained with 75 µg of U6>Ebf.3 sgRNA plasmid (Table 2). This was surprising given 
the much lower total amount of DNA electroporated from the PCR reaction relative to the 
plasmid prep (2.5 µg vs. 75 µg), and suggests that our sequencing assay is measuring the near-
maximal mutagenesis efficacy of each sgRNA. 
 
To assess whether unpurified sgRNA PCR cassettes could be used in CRISPR/Cas9-mediated 
loss-of-function experiments in F0 embryos, we assayed the expression of an Islet>GFP reporter 
in A10.57 motor neurons, which depends upon Ebf function (STOLFI et al. 2014). Indeed, 
Islet>GFP expression was downregulated in embryos electroporated with 
Sox1/2/3>nls::Cas9::nls and 25 µl of unpurified U6>Ebf.3 traditional PCR or 25µg U6>Ebf.3 
plasmid, but not with 25 µl (~2.5 µg) of unpurified U6>Negative Control sgRNA PCR cassette 
(Figure 4d). Taken together, these results indicate that unpurified PCR products can be used in 
lieu of plasmids to express sgRNAs for tissue-specific CRISPR/Cas9-mediated mutagenesis in 
Ciona embryos. 
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Pre-emptive design and scoring of all predicted sgRNAs for the Ciona genome 
While Ciona researchers will find the TuniCUT algorithm and the OSO-PCR method useful for 
sgRNA expression cassette assembly, we hoped to further empower the community by pre-
emptively designing all possible sgRNAs targeting at least one site in the Ciona genome 
(excluding those containing the PolIII-terminating sequence of more than three “T” in a row). 
We computationally identified 4,853,589 such sgRNAs (4,249,756 of them targeting a single site 
in the genome). We called this collection of predictions the CRISPR/Cas9-induced Ciona 
Knock-Out (Ci2KO) sgRNA Library. We used TuniCUT to predict the mutagenesis efficacy 
rates of each sgRNA in this library, and further pre-designed the requisite oligonucleotides to be 
used as primers for OSO-PCR to construct each sgRNA expression cassette. We have compiled 
all sgRNA sequences, their predicted efficacy rates, and corresponding OSO-PCR 
oligonucleotide sequences and have made this available in several formats (Figure 5, see 
Materials and methods for details), including as a genome annotation track hosted on the 
ANISEED Ciona genome browser (BROZOVIC et al. 2015). 
 
Discussion 
We have built a library of 83 plasmid vectors for the in vivo expression of sgRNAs targeting 23 
genes expressed in the cardiopharyngeal mesoderm and surrounding tissues, mostly 
hypothesized to be involved in regulating the specification of heart and/or pharyngeal muscles in 
Ciona, even though many have complex expression patterns and probably pleiotropic functions. 
We have also established a reliable protocol for the validation of sgRNA efficacy in 
electroporated Ciona embryos by next-generation sequencing. This allowed us to estimate the 
activity of most of these sgRNAs, which are ready to be used for future functional studies. 
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Figure 5. Whole-genome prediction and scoring of sgRNAs 
a) Screen shot of whole-genome pre-designed sgRNAs aligned to a part of the Ciona genome, viewed in the IGV 
browser. Bars in “TuniCUT” track represent each sgRNA, relative to KyotoHoya (KH) gene models depicted in 
bottom track. Height of sgRNA bars indicates predicted TuniCUT score. b) Zoom-in on the sequence of exon 2 (red 
dashed box in panel “a”) of the KH.C1.899 gene (Protein Phosphatase 1, Regulatory Subunit 42, or Ppp1r42). 
Underneath the representation of Ppp1r42 exon 2 and its amino acid sequence is the DNA sequence (small 
multicolored vertical bars) and the position all sgRNAs (red horizontal bars) predicted in this region (red horizontal 
bars). On top are TuniCUT scores (blue vertical bars) for each sgRNA, centered on each PAM. c) Detailed 
information relating to each sgRNA is immediately available, including protospacer sequence, genomic position, 
TuniCUT score, and sequences of primers for sgRNA cassette construction by OSO-PCR. These sequences can be 
copied by right-clicking on the desired sgRNA, and selecting “Copy Details to Clipboard”. 
 
By analyzing correlations between protospacer and flanking sequence nucleotide composition 
and sgRNA mutagenesis efficacy, we revealed principles that may contribute to Cas9:sgRNA 
activity. This prompted us to develop TuniCUT, an algorithm to predict relative sgRNA 
mutagenesis efficacy rates in Ciona. We demonstrate that TuniCUT functions well as a classifier 
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that allowed researchers to select, with greater confidence, potentially “good” sgRNAs with 
enough mutagenic activity for functional studies in F0. 
 
Some of the predictive sequence features have been identified in previous CRISPR/Cas9-
mediated mutagenesis screens performed in other metazoan model organisms, suggesting that 
these are determined by the intrinsic properties of sgRNAs and/or Cas9 (GAGNON et al. 2014; 
CHARI et al. 2015; MORENO-MATEOS et al. 2015). For instance, mutagenesis rate increases with 
increasing guanine content in the PAM-proximal nucleotides of the sgRNA, postulated to be due 
to increased sgRNA stability by G-quadruplex formation (MORENO-MATEOS et al. 2015). This 
would explain the specific enrichment for guanine but not cytosine, even if both could in theory 
augment sgRNA folding or binding to target DNA. Additionally, we encountered a depletion of 
thymine and cytosine in the PAM-proximal nucleotides of the protospacers for highly active 
sgRNAs, which has also been reported in other organisms. The strong negative correlation 
between sgRNA efficacy and thymine content of the protospacer is easily attributed to our use of 
the PolIII-dependent U6 promoter to express our sgRNAs. It has been shown that termination of 
transcription by PolIII is triggered by a string of thymines, and a high number of thymines 
clustered in the protospacer could result in lower sgRNA expression level due to premature 
termination of sgRNA transcription (STOLFI et al. 2014; WU et al. 2014). Likewise, depletion of 
adenine has been attributed to lower stability of sgRNAs (MORENO-MATEOS et al. 2015), 
suggesting that CRISPR/Cas9 mutagenesis efficacies are primarily determined by sgRNA 
transcription and degradation rates, which will vary depending on the species studied and the 
mode of sgRNA delivery (e.g. in vitro vs. in vivo synthesis). 
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Despite these general trends, several highly active sgRNAs had sequence features that defied the 
consensus, for instance by having more C than G at a PAM-proximal position. This suggests that 
there are multiple, possibly additive or synergistic factors that determine the mutagenesis 
efficacy, only one of which is primary sequence composition of the sgRNA or target. What those 
additional factors are will be an important topic of study as CRISPR/Cas9-based approaches are 
expanded to address additional questions in basic research as well as for therapeutic purposes. 
 
Despite legitimate concerns about potential off-target effects for functional studies, we were not 
able to detect CRISPR/Cas9-mediated mutagenesis at two potential off-target sites for the 
sgRNAs Ebf.3 and Fgf4/6.1. For the remainder of the sgRNAs, we purposefully selected those 
with zero predicted off-targets. This was possible in Ciona due to two factors. First, the Ciona 
genome is significantly smaller than the human genome and most metazoans, resulting in a lower 
number of identical protospacer seed sequences. Second, the GC content of the Ciona genome is 
only 35% as compared to 65% in humans, which results in a lower frequency of PAMs. Based 
on these considerations, we predict off-target effects to be less pervasive in Ciona than in other 
model organisms with more complex, GC-rich genomes. 
 
We designed all possible sgRNAs targeting the compact Ciona genome and calculated their 
predicted relative mutagenesis rates, which we have made available either as downloadable files 
for visualizing locally on the IGV browser (ROBINSON et al. 2011), or as a track on the 
ANISEED genome browser (BROZOVIC et al. 2015). This will allow researchers to locally 
browse for sgRNAs with predicted high activity targeting their loci of interest and select the 
corresponding pre-designed OSO-PCR oligonucleotide primers for rapid, efficient synthesis and 
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transfection. We expect this resource to facilitate the scaling of CRISPR/Cas9-mediated targeted 
mutagenesis and enable genome-wide screens for gene function in Ciona. 
 
Materials and Methods 
Target sequence selection and sgRNA design 
23 genes from Ciona robusta (formerly Ciona intestinalis type A)(HOSHINO AND TOKIOKA 1967; 
BRUNETTI et al. 2015) hypothesized to be important for cardiopharyngeal mesoderm 
development were shortlisted (Table 1) and one to four sgRNAs targeting non-overlapping 
sequences per gene were designed, for a total of 83 sgRNA vectors (Table 2). Two sgRNAs 
were designed to target the neurogenic bHLH factor Neurogenin, a gene that is not hypothesized 
to be involved in cardiopharyngeal development. Target sequences were selected by searching 
for N19 + NGG (protospacer + PAM) motifs and screened for polymorphisms and off-target 
matches using the GHOST genome browser and BLAST portal (SATOU et al. 2005; SATOU et al. 
2008). Potential off-targets were also identified using the CRISPRdirect platform (NAITO et al. 
2015). sgRNA expression plasmids were designed for each of these protospacers and constructed 
using the U6>sgRNA(F+E) vector as previously described (STOLFI et al. 2014), as well as a 
“Negative Control” protospacer that does not match any sequence in the C. robusta genome (5’-
GCTTTGCTACGATCTACATT-3’). Stretches of more than four thymine bases (T) were 
avoided due to potential premature transcription termination. Candidate sgRNAs with a partial 
PAM-proximal match of 13 bp or more were also discarded due to off-target concerns. All 
sgRNAs were designed to target protein-coding, splice-donor, or splice-acceptor sites, unless 
specifically noted. We preferred more 5’ target sites, as this provides a greater probability of 
generating loss-of-function alleles.  
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Electroporation of Ciona embryos 
DNA electroporation was performed on pooled, dechorionated zygotes (1-cell stage embryos) 
from C. robusta  adults collected from San Diego, CA (M-REP) as previously described 
(CHRISTIAEN et al. 2009). All sgRNA plasmid maxipreps were individually electroporated at a 
final concentration of 107 ng/µl (75 µg in 700 µl) concentration together with 
Eef1a1>nls::Cas9::nls plasmid (STOLFI et al. 2014) at 35.7 ng/µl (25 µg in 700 µl) 
concentration. For testing U6>Ebf.3 PCR or OSO-PCR, 25 µl was used instead of sgRNA 
plasmid. Embryos were then rinsed once in artificial sea water, to remove excess DNA and 
electroporation buffer, and grown at 18°C for 16 hours post-fertilization. 
 
Embryo lysis 
After 16 hpf, each pool of embryos targeted with a single sgRNA + Cas9 combination was 
washed in one sea water exchange before lysis, to remove excess plasmid DNA, and transferred 
to a 1.7 ml microcentrifuge tube. Excess sea water was then removed and embryos were lysed in 
50 µl of lysis mixture prepared by mixing 500 µL of DirectPCR Cell Lysis Reagent (Viagen 
Biotech Inc., Los Angeles, CA, Cat # 301-C) with 1 µl of Proteinase K (20 mg/ml, Life 
Technologies, Carlsbad, CA). The embryos were thoroughly mixed in lysis mixture and 
incubated at 68°C for 15 minutes, followed by 95°C for 10 minutes. 
 
PCR amplification of targeted sequences 
Targeted sequences were individually PCR-amplified directly from lysate from embryos targeted 
with the respective sgRNA, and from “negative control” lysate (from embryos electroporated 
with Eef1a1>nls::Cas9::nls and U6>Negative Control sgRNA vector). Primers 
(Supplementary Table 2) were designed to flank target sites as to obtain PCR products in the 
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/041632doi: bioRxiv preprint first posted online Feb. 28, 2016; 
size range of 108-290bp with an exception of the sequence targeted by Ebf.3 (“Ebf.774” in Stolfi 
et al. 2014) and Ebf.4 sgRNAs, for which the designed primers resulted in a product size of 350 
bp. Potential off-target sites predicted for sgRNAs Ebf.3 
(CTCGCAACGGGGACAACAGGGGG, genome position KhC8:2,068,844-2,068,866) and 
Fgf4/6.1 (TATTTTAATTCTGTACCTGTGGG, genome position KhC9:6,318,421-6,318,443) 
were amplified to test for off-target CRISPR/Cas9 activity with the primers: 5’- 
CCAGCACTTCAGAGCAATCA-3’ and 5’- TGACGTCACACTCACCGTTT-3’ (Ebf.3), and 
5’-AACGATTGTCCATACGAGGA-3’ and 5’-ACTTCCCAACAGCAAACTGG-3’ (Fgf/6.1). 
 
For each targeted sequence, 12.5 µL PCR reactions were set up with final concentrations of 600 
nM each primer, 300 µM dNTPs, 1 mM MgSO4, 2X buffer, and 0.05 U/µl Platinum Pfx DNA 
polymerase (Life Technologies), and subjected to the following PCR program: an initial cycle of 
10 minutes at 95°C, followed by 30 cycles of 30 seconds at 94°C, 30s at 60°C and 30s at 68°C, 
and a final cycle of 3 minutes at 68°C. PCR reactions were quickly checked on an agarose gel for 
the presence/absence of amplicon. Those that resulted in a single band were not initially purified. 
For those reactions with more than one band, the correct amplicon (selected based on expected 
size) was gel purified using a Nucleospin Gel Clean-up Kit (Macherey-Nagel, Düren, Germany). 
Purified and unpurified PCR products were then pooled for subsequent processing. The majority 
of PCR products amplified from larvae treated with Cas9 + gene-targeting sgRNA were pooled 
in Pool 1. All products from larvae treated with Cas9 + “negative control” sgRNA were pooled 
in Pool 2. For those sequences targeted by distinct sgRNAs but amplified using the same set of 
flanking primers, their PCR products were split into separate pools, as to allow for separate 
efficacy estimates.  
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Sequencing library preparation 
The PCR product pools were electrophoresed on ethidium bromide-stained, 1% agarose gel in 
0.5X Tris-Acetate-EDTA (TAE) buffer and a band of ~150-300 bp was excised (Nucleospin gel 
and PCR cleanup kit, Macherey-Nagel). 102-235 ng of each pool was used as a starting material 
to prepare sequencing libraries (protocol adapted from 
http://wasp.einstein.yu.edu/index.php/Protocol:directional_WholeTranscript_seq ). Ends were 
repaired using T4 DNA polymerase (New England Biolabs, Ipswich, MA) and T4 
Polynucleotide Kinase (New England Biolabs), and then A-tailed using Klenow fragment (3'→5' 
exo-) (New England Biolabs) and dATP (Sigma-Aldrich, St. Louis, MO). Each pool was then 
ligated to distinct barcoded adapters. (NEXTflex DNA Barcodes - BioO Scientific Cat# 514101). 
The six barcodes used in this study were: CGATGT, TGACCA, ACAGTG, GCCAAT, 
CAGATC and CTTGTA. At this step, the adapter-ligated DNA fragments were purified twice 
using Ampure XP beads (Beckman Coulter, Brea, CA). The final amplification, using primers 
included with NEXTflex adapters, was done using the PCR program: 2 minutes at 98°C followed 
by 8 cycles of 30 seconds at 98°C; 30 seconds at 60°C; 15 seconds of 72°C, followed by 10 
minutes at 72°C. Ampure XP bead-based selection was performed twice, and the libraries were 
quantified using qPCR. The libraries were then mixed in equimolar ratio to get a final DNA 
sequencing library concentration of 4 nM. The multiplexed library was sequenced by Illumina 
MiSeq V2 platform (Illumina, San Diego, CA) using 2x250 paired end configuration.  
 
Next generation sequencing data analysis 
FastQ files obtained from sequencing were de-multiplexed and subjected to quality control 
analysis. FastQ reads were mapped to the 2008 KyotoHoya genome assembly (SATOU et al. 
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2008) by local alignment using Bowtie2.2 (LANGMEAD AND SALZBERG 2012). Single end reads 
were also mapped to a reduced genome assembly consisting of only those scaffolds containing 
the targeted genes. This allowed for a much faster and accurate alignment using Bowtie2.2. The 
SAM file generated was converted into a BAM file using samtools (LI et al. 2009). The BAM 
file was sorted and indexed to visualize reads on Integrative Genomics Viewer (IGV) (ROBINSON 
et al. 2011). Most mutagenesis rates were obtained by counting indels in IGV. For some targets 
with partially overlapping aplicon sequences, custom Python scripts were written to parse the 
BAM file to get estimated rate of mutagenesis. Since a successful CRISPR/Cas9-mediated 
deletion or insertion should eliminate or disrupt all or part of the protospacer + PAM sequence 
(jointly termed the “pineapple”), we simply looked for mapped reads in which the pineapple was 
not fully present. When appropriate, the rate of naturally occurring indels around each target, as 
detected in reads from “negative control” embryos, was subtracted from the raw efficacy rates. 
 
Regression model for predicting sgRNA mutagenesis efficiency 
We based the sequence feature space on a 43-mer target site consisting of the protospacer 
sequence, PAM, and a 10-nucleotide contextual region flanking the protospacer to get a 
comprehensive set of features to inform a predictive mathematical model (10 nt 5’ flanking + 
Protospacer + PAM + 10 nt 3’ flanking). PAM-proximal G or C content, 43 single-nucleotide 
and 903 dual nucleotide (two nucleotides in all possible combinations at 43 positions) features  
were one-hot encoded using the Python scikit-learn machine learning module as a binary vector 
with a value of 1 representing the presence of a particular feature, while a value of 0 representing 
the absence of one. An L1 regularized lasso regression model was used to select 75 features that 
had the maximum effect on mutagenesis efficiency. The top and bottom 25% data points were 
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then used to train the model. Cross-validation was performed with 200 iterations but was not 
included in the analysis due to overfitting. 
 
Python scripts 
Custom python scripts were written to perform next-generation sequencing data analysis, 
regression modeling, and whole-genome sgRNA design. These are available upon request. 
Matplotlib (http://matplotlib.org) was used for plotting, Numpy (http://numpy.org) and Pandas 
(http://pandas.pydata.org) were used for data mining, and scikit-learn (http://scikit-learn.org) was 
used for machine learning. 
 
Combinatorial sgRNA electroporation to induce large deletions 
Embryos were electroporated with 25 µg Eef1a1>nls::Cas9::nls and two vectors from the set of 
validated sgRNA plasmids for each targeted gene (50 µg per sgRNA vector). Embryos were 
grown for 12 hpf at 18°C, pooled, and genomic DNA extracted from them using QIAamp DNA 
mini kit (Qiagen). Deletion bands were amplified in PCR reactions using Pfx platinum enzyme 
as described above (see “PCR amplification of targeted sequences”) and a program in which 
the extension time was minimized to 15 seconds only, in order to suppress the longer wild-type 
amplicon and promote the replication of the smaller deletion band. Primers used were 
immediately flanking the sequences targeted by each pair of sgRNAs (Supplementary Table 2). 
Products were purified from agarose gels, A-overhung and TOPO-cloned. Colonies were picked, 
cultured, prepped and sequenced. 
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Synthesis and electroporation of unpurified sgRNA PCR expression cassettes 
U6>Ebf.3 and U6>Negative Control sgRNA expression cassettes were amplified from their 
respective plasmids using the primers U6 forward (5’-TGGCGGGTGTATTAAACCAC-3’) and 
sgRNA reverse (5’-GGATTTCCTTACGCGAAATACG-3’) in reactions of final concentrations 
of 600 nM each primer, 300 µM dNTPs, 1 mM MgSO4, 2X buffer, and 0.05 U/µl Platinum Pfx 
DNA polymerase (Life Technologies), and subjected to the following PCR program: an initial 
cycle of 3 minutes at 95°C, followed by 30 cycles of 30 seconds at 94°C, 30s at 55°C and 2 
minutes at 68°C, and a final cycle of 5 minutes at 68°C. U6>sgRNA(F+E)::eGFP (STOLFI et al. 
2014)  was amplified as above but using Seq forward primer (5’- 
AGGGTTATTGTCTCATGAGCG-3’) instead. For phenotyping Ebf-dependent expression of 
Islet reporter in A10.57 motor neurons (STOLFI et al. 2014), embryos were co-electroporated 
with 35 µg of Sox1/2/3> nls::Cas9::nls, 5 µg of Sox1/2/3>H2B::mCherry, 30 µg of Isl>eGFP , 
and either 25 µg of U6>Ebf.3 plasmid or 25 µl (~2.5 µg) of unpurified PCR product. 
 
sgRNA expression cassette assembly by One-step Overlap PCR (OSO-PCR) 
sgRNA PCR cassettes were constructed using an adapted One-step Overlap PCR (OSO-PCR) 
protocol (URBAN et al. 1997). Basically, a desired protospacer sequence is appended 5’ to a 
forward primer (5’-GTTTAAGAGCTATGCTGGAAACAG-3’) and its reverse complement is 
appended 5’ to a reverse primer (5’-ATCTATACCATCGGATGCCTTC-3’). These primers are 
then added to a PCR reaction at limiting amounts, together with U6 forward (5’-
TGGCGGGTGTATTAAACCAC-3’) and sgRNA reverse (5’-
GGATTTCCTTACGCGAAATACG-3’) primers and separate template plasmids containing the 
U6 promoter (U6>XX) and the sgRNA scaffold (XX>sgRNA F+E). Plasmids are available from 
Addgene (https://www.addgene.org/Lionel_Christiaen/). The complementarity between the 5’ 
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ends of the inner primers bridges initially separate U6 and sgRNA scaffold sequences into a 
single amplicon, and because they are quickly depleted, the entire cassette is preferentially 
amplified in later cycles by the outer primers (see Figure 4 and Supplementary Protocol for 
details). Final, unpurified reactions should contain PCR amplicon at ~100 ng/µl, as measured by 
image analysis after gel electrophoresis (Supplementary Figure 4). 
 
TuniCUT and Ci2KO sgRNA Library 
The TuniCUT script and supporting databases can be downloaded from github 
(https://github.com/shashank357/TuniCUT) and run in Python 3.5. Whole-genome sgRNA 
predictions and oligo designs (“Ci2KO” library) are available for download as a GFF3 file or a 
BED file available upon request, for local browsing in the IGV browser. To get the sequences of 
primers for OSO-PCR in IGV, right-click on the desired sgRNA and select “Copy Details to 
Clipboard”. Ci2KO can also be visualized in the genome browser at ANISEED 
(http://www.aniseed.cnrs.fr/fgb2/gbrowse/ciona_intestinalis/). 
 
Embryo imaging 
Fluorescent in situ hybridization of eGFP or Foxf coupled to immunohistochemsitry was carried 
out as previously described (BEH et al. 2007; STOLFI et al. 2014). Images were taken on a Leica 
Microsystems inverted TCS SP8 X confocal microscope or a Leica DM2500 epifluorescence 
microscope. Mouse monoclonal anti-β-Gal Z3781 (Promega, Madison, WI) was used diluted at 
1:500. Goat anti-Mouse IgG (H+L) Secondary Antibody Alexa Fluor 568 conjugate (Life 
Technologies) was used diluted at 1:500. 
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Supplementary Table 1. All sgRNAs sorted by decreasing mutagenesis efficacy (Mut%) 
 
sgRNA Mut% 
Htr7-r.2 59.63 
Rhod/f.1 58.36 
Htr7-r.1 58.11 
Ddr.4 46.96 
Nk4.2 46.00 
Htr7-r.3 43.99 
Islet.2  43.93 
Lef1.2 43.58 
Gata4/5/6.1 43.22 
Ddr.2 42.40 
Rhod/f.3 40.71 
Gata4/5/6.3 40.68 
Fgf8/17/18.1  39.86 
Tle.b.3 39.10 
Foxf.4 38.78 
Ets.b.3 38.30 
Foxg-r.2 38.14 
Bmp2/4.4 37.83 
Nk4.3 37.79 
Ffg4/6.1 37.51 
Ebf.3 37.27 
Eph.a.3 37.11 
Htr7-r.4 35.87 
Hand.1 35.52 
Gata4/5/6.4 35.41 
Eph.a.2 34.97 
Mrf.2 32.85 
Ddr.5 32.81 
Mrf.3 32.61 
Fgf8/17/18.2  31.21 
Hand.2 30.98 
Ffgr.2 30.39 
Lef1.1 30.08 
Fzd5/8.3 29.59 
Foxf.1 29.05 
Foxf.3 28.70 
Tll.1 27.47 
Tle.b.1 27.03 
Tle.b.2 26.32 
Bmp2/4.2 24.91 
Ebf.1 24.59 
Ffgr.4 24.29 
Ffgr.1 24.15 
Fzd5/8.2 23.83 
Neurog.1 23.57 
Eph.a.1 23.17 
Hand.4 23.07 
Rhod/f.2 22.40 
Hand-r.2 21.96 
Ffg4/6.3 20.65 
Ffg4/6.2 19.59 
Fzd5/8.4 18.52 
Foxf.2 17.61 
Mrf.1 15.49 
Fzd5/8.1 15.09 
Nk4.1 14.13 
Nk4.4 13.81 
Gata4/5/6.2 13.74 
Bmp2/4.3 12.86 
Hand-r.1 12.27 
Tll.4 10.70 
Ffg4/6.4 10.24 
Foxg-r.3 10.16 
Ets.b.1 9.31 
Hand-r.3 8.80 
Tle.b.4 6.96 
Ets.b.2 5.72 
Mrf.4 5.25 
Hand.3 5.22 
Ebf.2 4.97 
Ddr.1 3.84 
Rhod/f.4 3.52 
Ddr.3 3.33 
Tll.2 2.37 
Ffgr.3 2.33 
Tll.3 2.22 
Foxg-r.1 1.87 
Hand-r.4 0.75 
Foxg-r.4 0.34 
Ets.b.4 0.12 
Ebf.4 0.05 
Neurog.2 0.00 
Bmp2/4.1 0.00 
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 Supplementary Table 2. List of Primers (5’ -> 3’) used to amplify loci for deep sequencing. 
 
Forward Primer (5' -> 3') Reverse Primer (5' -> 3') gRNAs assayed 
GGACGCGATAGTCAACGAAT GGCTCGCAATATCTTCATGC Bmp2/4.1 
CGACTACTACGAGCCCGAAC GCCGAGAAAACAAAATTTTCAA Bmp2/4.2 
TCATTAGCGCGATGGATGT ATCGTCCGGAGGCATTTT Bmp2/4.3, Bmp2/4.4 
AAACGTCAACGCTGAAAAGC GTATTGAAGCCGCCAAGAAA Ddr.1 
TGTAGTTGCTCCTCCACACG CACACCATCAGTCAACTGTCC Ddr.2 
CACATAATATGTGCCAACTCG CCCTAATACAACACGAACCTC Ddr.3, Ddr.4 
TGACGTAGCCACACTTATAGG AACTGGGTTACACATGTCAC Ddr.5 
CCGCCAAACAACCTTAGAAA GTGTCCCATCTTACCCCACA Ebf.1 
AAGTAATATCCAAATGGCAACAATG AACTTAACACAAATATCGGTCAGATT Ebf.2 
CATTGACCATCCTGAACGAA ACGGGAAAACGAAATGAACA Ebf.3, Ebf.4 
TTCCAAGTTTGTCACATTCGAT TGAAAACGTGTCTCATCTTACCC Eph.a.1 
GCGAGCACGAGGTGTATGTA TGTATAATCCTCTGCTTCTGATCG Eph.a.2 
TGCATATCCTCCACACAGGA CAGTCTCGCAATAACAACAAGC Eph.a.3 
GCATCCCATCTTTGGATGAA TCCTCGTGTCATTTCCACAT Ets.b.1, Ets.b.2 
AGCTCTGCCTAAGTCTATTACCG CATCTTAAACTCCCAGCCATC Ets.b.3 
GTGGTCCAATCCAACTGTGG TCGATTCTAAACTCCAGCAATG Ets.b.4 
GCTGTGGATTACTATAAATAGCACTGT CTGTTTTCCACAGCAGCAGA Fgf4/6.1 
GAAGATGGTATAAGCACTCAGCAA TACACCGTAGGACGAGCAAG Fgf4/6.2, Fgf4/6.3 
GGAAATGAGAAGCTTCGAAAGA AATTCCGATGGAAGGAGGTT Fgf4/6.4 
TTTCTCACAATGATCGGTATACAAAC TCCCAGAAAAGACCTCGTTG Fgf8/17/18.1 
GAATCCCCGATCCCCATA ATATAACTGTAGCCTTGAGACTC Fgf8/17/18.2 
GAATGAAACCAAACCCCTCA AGGAACGAATAAACAATGCTGA Fgfr.1 
CCCCAACGTATCCCATCTTA GACGATCCGTAGTTGTAGATGC Fgfr.2 
TCTTGGGTAATGGCCAACTC CCCCCAGTCTTCCATTCTTC Fgfr.3 
TTGGAGTCGGTGATAATGTCC ACATGCTACCTTTGTGCTAGTGA Fgfr.4 
ACCACCGACCCAACTTAATG TGGACAGAAGTGTTTGTTCCAG Foxf.1, Foxf.2 
GAATCCCCGATCCCCATA ATCAATATGGCGGAAAACGA Foxf.3 
TGGAAATGGGAAAGGCTTAC TTAAAGCGCTGCTCTCTCG Foxf.4 
CCGAACAAAACAGTCGTTTC TAATTAGATGCCCGGGACTG Foxg-r.1 
CACACACATACCCCGCATTA TCATGATAAGCGGGAAACAA Foxg-r.2 
GGAGAATCGACCAACGTGAG CGTTGACATGTTTGTACCTTCG Foxg-r.3, Foxg-r.4 
GCGAACCTATCCAAGTACCG CCATTAAACGGTTTGTCTAAGAATG Fzd5/8.1 
TATGTCGAAGTTCGCGGTTG TTCCTAAACCTATGATTTAACTGACCT Fzd5/8.2, Fzd5/8.3 
GGTATTCCATTTTACCCCACA TGCTTTTTAACGCTGGGATA Fzd5/8.4 
CGTTCCAGATTCATCCCATC CCAAGTTTTGCTGTGTGACG Gata4/5/6.1 
CAGCATGACTAACCTTGTATTCCA CACGCTAACGCAAAGTAGCC Gata4/5/6.2, Gata4/5/6.3 
CCCGCAAAGATACGACTACC ATGCTTCCGGCTGTAGTGTT Gata4/5/6.4 
GTAACGTCCGGCAGAAAGAA CTTTCTACGTTCGCGGGATT Hand.1, Hand.2 
TGGCGTCTTCCTATATTGCTT TGGTTTAAAAGCGCTTCATT Hand.3 
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GACGCTTCTGCAACTGCTTA TCAGTTTATCACCGCAGCAG Hand.4 
AACGTGGCGGATTCACAAT CGACGACTCATACGGCTCTT Hand-r.1, Hand-r.2 
CTCCCTTATACCCCACACAGTT CCAGCTAGCGGTGGTGTAGT Hand-r.3 
TCCGAGTCACCCGTATTATCA ATTCTATCGCGCAGATCGTC Hand-r.4 
GCGGTTGCGACACTAAAGAT CCCACCCTCTATTCCGAAAC Htr7-r.1, Htr7-r.2 
TAACGCTGTGTGAACGCACT AAGGTGTCCCATCTTTCCCTA Htr7-r.3 
CGACTCCCATAGACCGTTG ACAAAGATGGCGGTCGATAC Htr7-r.4 
CGAATCATTCGCCATTTTCG TCAACCCTGGCCTGATTTC Isl.1 
TTACTTGCGCGTGTTTTCAG AGCATGCCACTCAAGGTTG Isl.2 
GCGCGTACTGGATTACTTGG TCTTCTTCCTCGACTAAATCACC Lef1.1 
AAAGGGTAGGCGAAGAGGAC ACACCAACTAAAACGCTAATATGTAA Lef1.2 
GGAGCTCGACCTCTCTTCAA ATATCGCTCTTTTCCGCATC Mrf.1, Mrf.2 
CAAACGGCCATCAATGTTTAG TGTTGGTCGCCATACAACATA Mrf.3, Mrf.4 
CTTCTGTTGTTCCGACAAGC AGTCATACCAAAATGAGCCAC Neurog.1 
TCCAAAAAGACACAGTCAACAG ACCTTAATTCTTCTAGTGCGTC Neurog.2 
GTGGTCGTCGATTTTCCATC GCTAATTCCCATTCCGCTTA Nk4.1, Nk4.2 
CTGTTCTCCCAGGCACAAGT CGCGAACTAAAACAGGAACTG Nk4.3, Nk4.4 
AACTTGTAAAGCCAAAACTATACACAA TTAAACGTAAACTTACTTCAGGGAAT Rhod/f.1 
TAGGGCGAGCAGGATAATTG CACTTCCATGCTAACCGAAA Rhod/f.2, Rhod/f.3 
CAAATGTTTACTTGTACCAGGTCAG ATCCGAGTTCACCTGAGACC Rhod/f.4 
TCAACGTCCTTTGTTTGTGG GGTGCCAGCTTCGACCTAT Tle.b.1 
TGGAACATTATGAGATTAGGACTTCA CGTTTAACGGATGAGGAGGT Tle.b.2, Tle.b.3, Tle.b.4 
TGGCGACATTGCTTTAGATG ACTTTCTGTTCCGCCGTCT Tll.1 
CCCCATTCTTATCAGTTGCTTT CGTCGTCTGGATACCTCTCG Tll.2 
ACCACCGGCGATACATTAAG AACTGATGTTTAACTAATACCTTTTCG Tll.3 
TTGGTTAGGGATTGTCGTTTT ATGGGGCCATTTTCTCTCTT Tll.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/041632doi: bioRxiv preprint first posted online Feb. 28, 2016; 
  
Supplementary Table 3. Contribution of dual nucleotide features to mutagenesis efficacy. 
Co-occurrence of specific nucleotides at two given positions (X and Y, e.g. -4C = “C” at position -4. +2G = “G” at 
position +2) of the 43-mer target site (10 nt 5’ flanking + Protospacer + PAM + 10 nt 3’ flanking, see Figure 2 for the 
exact annotation of positions) and their overall contribution to mutagenesis efficacy (Mut%) of the associated sgRNA, 
as determined by lasso regression. Contribution is given as percentage points of total mutagenesis efficacy rate. 
Asterisks indicate those dual nucleotide features that are, in effect, single nucleotide features since one of the positions 
does not vary in our data set (e.g. all sgRNAs have “G” at position 1, and all PAMs are of the sequence “NGG”). 
 
Nucleotide 
X 
Nucleotide 
Y 
Contribution 
to Mut% 
-7C 12G 13.17 
-3A 16T 7.74 
-10C +5T 7.23 
12A +8C 6.95 
13T +7C 6.69 
-4A 11G 5.76 
-1T +3A 5.19 
-1T +4G 4.16 
-10C +2A 3.85 
-8A 5T 3.74 
+1T +3T 3.58 
-10T -5G 3.43 
3A 12T 3.14 
-8A +3T 2.75 
3A +2A 2.63 
20G +9C 2.61 
3A 17G 2.49 
-8A 9G 2.26 
-8T 6G 1.79 
6A +8T 1.74 
-9T 1G 1.51 
1G 17G 1.37* 
-9T PAM[2]G 1.34* 
5T 15T 1.26 
-9A 10T 1.15 
10G 11G 1.07 
-10T +8T 0.82 
1G 18G 0.77* 
12A +3T 0.67 
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10A +9T 0.57 
8T 19G 0.54 
13G +3A 0.44 
1G 20G 0.37* 
-6T 17G 0.29 
1G 8A 0.21* 
7G 20G 0.12 
-7C 16C 0.11 
19G +3T 0.1 
1G 6G 0.02* 
6A PAM[2]G 0.01* 
8T PAM[2]G 0.01* 
17A PAM[2]G 0.01* 
6A 10C -0.02 
-3G PAM[1]T -0.04 
+1T +4T -0.04 
1G 17C -0.07* 
2G +3C -0.1 
-7G 14G -0.13 
3T 20C -0.44 
-7G +2T -0.79 
17C PAM[1]T -0.86 
-5A 11A -1.03 
1G 8C -1.03* 
5A 8G -1.07 
-2A 12C -1.19 
-8G +10C -1.79 
-9T +7G -1.99 
-10C +2T -2.16 
PAM[1]T +6A -2.21 
-6T 17A -2.31 
6A +8G -4.84 
-8T +10A -5.14 
+1C +6A -5.14 
PAM[1]T +7T -6.49 
-2A 3T -7.45 
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Supplementary Table 4. Contributions of single nucleotide features to mutagenesis efficacy 
 
Nucleotide X Contribution to Mut% 
20G 5.26 
18G 3.60 
17G 0.77 
-9A 0.72 
6G 0.34 
8A 0.05 
17C -0.44 
8C -1.00 
+3C -4.65 
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Supplementary Figure 1. Log-odds score plot for bottom 25% sgRNAs 
Log-odds scores depicting the frequency of occurrence for nucleotides in the bottom 25% (least effective) sgRNAs, 
at all positions of the protospacer, PAM, and flanking regions. Position “1” of the protospacer has been omitted from 
the analysis, due to this always being “G” for PolIII-dependent transcription of U6-promoter-based vectors. 
Likewise, the “GG” of the PAM has also been omitted, as this sequence is invariant in all targeted sites. 
 
 
 
 
 
 
 
 
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/041632doi: bioRxiv preprint first posted online Feb. 28, 2016; 
 Supplementary Figure 2. Other examples of large deletions obtained by combinatorial action of two 
sgRNAs 
Sequence alignments of clones for each locus, amplified from embryos in which two sgRNAs were used for 
CRISPR/Cas9-induced site mutagenesis. 
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 Supplementary Figure 3. In vivo gene expression from electroporated unpurified PCR products 
In situ hybridization of eGFP in late gastrula/early neural stage embryos electroporated with either U6> 
sgRNA(F+E)::eGFP plasmid (20 µg) or unpurified PCR product (50 µl, ~5 µg DNA). 
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Supplementary Figure 4. Quantification of OSO-PCR products 
Image of gel electrophoresis of varying amounts of linearized plasmid and unpurified OSO-PCR products. Pixel 
intensity analysis in ImageJ was performed as previously described (STOLFI et al. 2014), and indicated that the 
sgRNA expression cassette in unpurified OSO-PCR reactions are at a concentration of approximately 100 ng/µl. 
 
 
 
 
 
 
 
 
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/041632doi: bioRxiv preprint first posted online Feb. 28, 2016; 
REFERENCES 
Abdul-Wajid, S., H. Morales-Diaz, Stephanie M. Khairallah and William C. Smith, 2015 T-type 
Calcium Channel Regulation of Neural Tube Closure and EphrinA/EPHA Expression. 
Cell Reports 13: 829-839. 
Barrangou, R., C. Fremaux, H. Deveau, M. Richards, P. Boyaval et al., 2007 CRISPR provides 
acquired resistance against viruses in prokaryotes. Science 315: 1709-1712. 
Beh, J., W. Shi, M. Levine, B. Davidson and L. Christiaen, 2007 FoxF is essential for FGF-
induced migration of heart progenitor cells in the ascidian Ciona intestinalis. 
Development 134: 3297-3305. 
Brozovic, M., C. Martin, C. Dantec, D. Dauga, M. Mendez et al., 2015 ANISEED 2015: a digital 
framework for the comparative developmental biology of ascidians. Nucleic acids 
research: gkv966. 
Brunetti, R., C. Gissi, R. Pennati, F. Caicci, F. Gasparini et al., 2015 Morphological evidence that 
the molecularly determined Ciona intestinalis type A and type B are different species: 
Ciona robusta and Ciona intestinalis. Journal of Zoological Systematics and 
Evolutionary Research 53: 186-193. 
Chari, R., P. Mali, M. Moosburner and G. M. Church, 2015 Unraveling CRISPR-Cas9 genome 
engineering parameters via a library-on-library approach. Nature methods 12: 823-
826. 
Chen, B., L. A. Gilbert, B. A. Cimini, J. Schnitzbauer, W. Zhang et al., 2013 Dynamic imaging of 
genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155: 
1479-1491. 
Cho, S. W., S. Kim, Y. Kim, J. Kweon, H. S. Kim et al., 2014 Analysis of off-target effects of 
CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome research 24: 
132-141. 
Christiaen, L., E. Wagner, W. Shi and M. Levine, 2009 The sea squirt Ciona intestinalis. Cold 
Spring Harbor protocols 2009: pdb. emo138. 
Cong, L., F. A. Ran, D. Cox, S. Lin, R. Barretto et al., 2013 Multiplex genome engineering using 
CRISPR/Cas systems. Science 339: 819-823. 
Crooks, G. E., G. Hon, J.-M. Chandonia and S. E. Brenner, 2004 WebLogo: a sequence logo 
generator. Genome research 14: 1188-1190. 
Dickinson, D. J., J. D. Ward, D. J. Reiner and B. Goldstein, 2013 Engineering the Caenorhabditis 
elegans genome using Cas9-triggered homologous recombination. Nature methods 
10: 1028-1034. 
Diogo, R., R. G. Kelly, L. Christiaen, M. Levine, J. M. Ziermann et al., 2015 A new heart for a 
new head in vertebrate cardiopharyngeal evolution. Nature 520: 466-473. 
Doench, J. G., E. Hartenian, D. B. Graham, Z. Tothova, M. Hegde et al., 2014 Rational design of 
highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nature 
biotechnology. 
Fu, Y., J. A. Foden, C. Khayter, M. L. Maeder, D. Reyon et al., 2013 High-frequency off-target 
mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature biotechnology 
31: 822-826. 
Fu, Y., J. D. Sander, D. Reyon, V. M. Cascio and J. K. Joung, 2014 Improving CRISPR-Cas 
nuclease specificity using truncated guide RNAs. Nature biotechnology 32: 279-284. 
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/041632doi: bioRxiv preprint first posted online Feb. 28, 2016; 
Gagnon, J. A., E. Valen, S. B. Thyme, P. Huang, L. Ahkmetova et al., 2014 Efficient mutagenesis 
by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of 
single-guide RNAs. 
Gantz, V. M., and E. Bier, 2015 The mutagenic chain reaction: A method for converting 
heterozygous to homozygous mutations. Science 348: 442-444. 
Hanley, J. A., and B. J. McNeil, 1982 The meaning and use of the area under a receiver 
operating characteristic (ROC) curve. Radiology 143: 29-36. 
Hirano, T., and H. Nishida, 1997 Developmental Fates of Larval Tissues after Metamorphosis 
in Ascidian Halocynthia roretzi I. Origin of Mesodermal Tissues of the Juvenile. 
Developmental biology 192: 199-210. 
Hoshino, Z. i., and T. Tokioka, 1967 An unusually robust Ciona from the northeastern coast 
of Honsyu Island, Japan. 
Hotta, K., K. Mitsuhara, H. Takahashi, K. Inaba, K. Oka et al., 2007 A web-based interactive 
developmental table for the ascidian Ciona intestinalis, including 3D real-image 
embryo reconstructions: I. From fertilized egg to hatching larva. Developmental 
Dynamics 236: 1790-1805. 
Hsu, P. D., D. A. Scott, J. A. Weinstein, F. A. Ran, S. Konermann et al., 2013 DNA targeting 
specificity of RNA-guided Cas9 nucleases. Nature biotechnology 31: 827-832. 
Hwang, W. Y., Y. Fu, D. Reyon, M. L. Maeder, S. Q. Tsai et al., 2013 Efficient genome editing in 
zebrafish using a CRISPR-Cas system. Nature biotechnology 31: 227-229. 
Imai, K. S., K. Hino, K. Yagi, N. Satoh and Y. Satou, 2004 Gene expression profiles of 
transcription factors and signaling molecules in the ascidian embryo: towards a 
comprehensive understanding of gene networks. Development 131: 4047-4058. 
Jinek, M., K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna et al., 2012 A programmable dual-
RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816-
821. 
Jinek, M., A. East, A. Cheng, S. Lin, E. Ma et al., 2013 RNA-programmed genome editing in 
human cells. eLife 2. 
Langmead, B., and S. L. Salzberg, 2012 Fast gapped-read alignment with Bowtie 2. Nature 
methods 9: 357-359. 
Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan et al., 2009 The sequence alignment/map 
format and SAMtools. Bioinformatics 25: 2078-2079. 
Mali, P., L. Yang, K. M. Esvelt, J. Aach, M. Guell et al., 2013 RNA-guided human genome 
engineering via Cas9. Science 339: 823-826. 
Moreno-Mateos, M. A., C. E. Vejnar, J.-D. Beaudoin, J. P. Fernandez, E. K. Mis et al., 2015 
CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. 
Nature methods 12: 982-988. 
Naito, Y., K. Hino, H. Bono and K. Ui-Tei, 2015 CRISPRdirect: software for designing 
CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics 31: 1120-1123. 
Ng, A. Y., 2004 Feature selection, L 1 vs. L 2 regularization, and rotational invariance, pp. 78 
in Proceedings of the twenty-first international conference on Machine learning. ACM. 
Nishida, H., 1987 Cell lineage analysis in ascidian embryos by intracellular injection of a 
tracer enzyme: III. Up to the tissue restricted stage. Developmental biology 121: 526-
541. 
Nishiyama, A., and S. Fujiwara, 2008 RNA interference by expressing short hairpin RNA in 
the Ciona intestinalis embryo. Development, growth & differentiation 50: 521-529. 
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/041632doi: bioRxiv preprint first posted online Feb. 28, 2016; 
Pasini, A., A. Amiel, U. Rothbächer, A. Roure, P. Lemaire et al., 2006 Formation of the ascidian 
epidermal sensory neurons: insights into the origin of the chordate peripheral 
nervous system. PLoS Biology 4: e225. 
Pattanayak, V., S. Lin, J. P. Guilinger, E. Ma, J. A. Doudna et al., 2013 High-throughput profiling 
of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. 
Nature biotechnology 31: 839-843. 
Razy-Krajka, F., K. Lam, W. Wang, A. Stolfi, M. Joly et al., 2014 Collier/OLF/EBF-Dependent 
Transcriptional Dynamics Control Pharyngeal Muscle Specification from Primed 
Cardiopharyngeal Progenitors. Developmental cell 29: 263-276. 
Ren, X., Z. Yang, J. Xu, J. Sun, D. Mao et al., 2014 Enhanced specificity and efficiency of the 
CRISPR/Cas9 system with optimized sgRNA parameters in Drosophila. Cell reports 9: 
1151-1162. 
Robinson, J. T., H. Thorvaldsdóttir, W. Winckler, M. Guttman, E. S. Lander et al., 2011 
Integrative genomics viewer. Nature biotechnology 29: 24-26. 
Rothbächer, U., V. Bertrand, C. Lamy and P. Lemaire, 2007 A combinatorial code of maternal 
GATA, Ets and β-catenin-TCF transcription factors specifies and patterns the early 
ascidian ectoderm. Development 134: 4023-4032. 
Sasaki, H., K. Yoshida, A. Hozumi and Y. Sasakura, 2014 CRISPR/Cas9 ‐mediated gene 
knockout in the ascidian Ciona intestinalis. Development, growth & differentiation 
56: 499-510. 
Satoh, N., 2013 Developmental genomics of ascidians. John Wiley & Sons. 
Satou, Y., T. Kawashima, E. Shoguchi, A. Nakayama and N. Satoh, 2005 An integrated database 
of the ascidian, Ciona intestinalis: towards functional genomics. Zoological science 22: 
837-843. 
Satou, Y., K. Mineta, M. Ogasawara, Y. Sasakura, E. Shoguchi et al., 2008 Improved genome 
assembly and evidence-based global gene model set for the chordate Ciona 
intestinalis: new insight into intron and operon populations. Genome Biology 9: R152. 
Schneider, T. D., and R. M. Stephens, 1990 Sequence logos: a new way to display consensus 
sequences. Nucleic acids research 18: 6097-6100. 
Shalem, O., N. E. Sanjana, E. Hartenian, X. Shi, D. A. Scott et al., 2014 Genome-scale CRISPR-
Cas9 knockout screening in human cells. Science 343: 84-87. 
Stolfi, A., T. B. Gainous, J. J. Young, A. Mori, M. Levine et al., 2010 Early chordate origins of the 
vertebrate second heart field. Science 329: 565. 
Stolfi, A., S. Gandhi, F. Salek and L. Christiaen, 2014 Tissue-specific genome editing in Ciona 
embryos by CRISPR/Cas9. Development 141: 4115-4120. 
Tibshirani, R., 1996 Regression shrinkage and selection via the lasso. Journal of the Royal 
Statistical Society. Series B (Methodological): 267-288. 
Urban, A., S. Neukirchen and K.-E. Jaeger, 1997 A rapid and efficient method for site-directed 
mutagenesis using one-step overlap extension PCR. Nucleic acids research 25: 2227-
2228. 
Wang, H., H. Yang, C. S. Shivalila, M. M. Dawlaty, A. W. Cheng et al., 2013a One-step generation 
of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome 
engineering. Cell 153: 910-918. 
Wang, W., F. Razy-Krajka, E. Siu, A. Ketcham and L. Christiaen, 2013b NK4 antagonizes 
Tbx1/10 to promote cardiac versus pharyngeal muscle fate in the ascidian second 
heart field. PLoS Biology 11: e1001725. 
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/041632doi: bioRxiv preprint first posted online Feb. 28, 2016; 
Wu, X., D. A. Scott, A. J. Kriz, A. C. Chiu, P. D. Hsu et al., 2014 Genome-wide binding of the 
CRISPR endonuclease Cas9 in mammalian cells. Nature biotechnology 32: 670-676. 
Zeller, R. W., M. J. Virata and A. C. Cone, 2006 Predictable mosaic transgene expression in 
ascidian embryos produced with a simple electroporation device. Developmental 
Dynamics 235: 1921-1932. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/041632doi: bioRxiv preprint first posted online Feb. 28, 2016; 
Supplemental Protocol 
 
ONE-STEP OVERLAP PCR (OSO-PCR) TO MAKE READY-TO-ELECTROPORATE SINGLE GUIDE RNA (sgRNA) 
EXPRESSION CASSETTES – updated 02/26/2016 
 
Companion manuscript: 
Rational design and whole-genome predictions of single guide RNAs for efficient 
CRISPR/Cas9-mediated genome editing in Ciona 
Shashank Gandhi, Lionel Christiaen and Alberto Stolfi 
 
Primers for OSO-PCR ready to be ordered can be copied from each sgRNA entry in the Ci2KO library (in 
IGV, right-click on the desired sgRNA and select “Copy Details to Clipboard”). Use CRISPRdirect 
(http://crispr.dbcls.jp/) to cross-references with the JGI v.2 Ciona intestinalis genome for potential off-
targets. Avoid any sgRNA that has a “12mer+PAM” off-target in the genome. Check for polymorphisms 
using the Kyoto University Ghost Database genome browser (http://ghost.zool.kyoto-u.ac.jp/cgi-
bin/gb2/gbrowse/kh/). To design OSO-PCR primers de novo, follow the instructions: 
 
1- Select your target, as identified by online tools such as CRISPRdirect (see above). 
 
                   target      PAM        
...TCAACCCAACTGAGGGTTGGACAACAGGTGGAGCAACAGT... 
 
2- A target (the protospacer) is given as N(20). If the target sequence contains too many T’s (three or 
more T’s clustered together tend to terminate transcription), or if it spans many known naturally-
occurring polymorphisms, or has a high number of potential off-targets, discard it. 
 
3- For transcription initiation from U6 promoter, replace the first base of the target with a “G”, to give a 
G+(N)19 sequence. 
 
GCTGAGGGTTGGACAACAGG 
 
4- Append “GTTTAAGAGCTATGCTGGAAACAG” to the 3’ end of the sequence. This entire sequence is 
now the forward primer used to PCR the sgRNA scaffold part of the cassette (“OSO forward” primer) 
 
GCTGAGGGTTGGACAACAGGGTTTAAGAGCTATGCTGGAAACAG 
  
5- Copy reverse complement of G+N(19), append “ATCTATACCATCGGATGCCTTC” to the 3’ end of this. 
This is now the reverse primer to PCR the U6 promoter part of the cassette (“OSO reverse” primer) 
 
CCTGTTGTCCAACCCTCAGCATCTATACCATCGGATGCCTTC 
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6- Set up a PCR reaction using the following components in the exact amounts described. The 
amounts/concentrations/proportions are critical for the one-step overlap reaction to occur seamlessly. 
Also, it is very important to eliminate all sources of contamination, otherwise you may re-amplify 
sgRNAs already in heavy use in the lab. Template plasmids are available from Addgene 
(https://www.addgene.org/Lionel_Christiaen/): 
 
For 50 ul reaction: 
1.5 ul 10mM dNTPs 
1 ul 50mM MgSO4 
10 ul 10X Pfx Buffer 
1 ul U6>XX plasmid at 15 ng/ul 
1 ul X>sgRNA(F+E) plasmid at 15 ng/ul 
1.5 ul 20 uM U6 forward primer (5’- TGGCGGGTGTATTAAACCAC -3’) 
1.5 ul 20 uM sgRNA reverse primer (5’- GGATTTCCTTACGCGAAATACG -3’) 
1 ul 2 uM OSO forward primer (designed in step 4, or obtained from TuniCUT/Ci2KO) 
1 ul 2 uM OSO reverse primer (designed in step 5, or obtained from TuniCUT/Ci2KO) 
30 ul H2O 
0.5 ul Pfx platinum 
 
PCR program: 
94° - 3’ 
94° - 30” | 
50° - 30” | X 30 
68° - 3’ | 
68° - 5’ 
 
 
The 1:10 dilution of your custom overlap target-specific primers will force the “fusion” of the entire 
cassette later in the reaction, when these primers are depleted from the solution through incorporation 
into the PCR products. 
 
7- Run 2 ul of the PCR reaction on a gel. There should be a strong band at ~1.2 kbp. If the band is only 1 
kbp, the fusion did not occur. The success rate in our hands is ~94%. If possible, run alongside positive 
control (PCR on verified sgRNA plasmid template using same primers). 
 
OSO-PCR products can be electroporated as is, un-purified. 25 ul appears to be sufficient to recapitulate 
effects of sgRNAs delivered by traditional plasmid electroporation, but this volume can be adjusted 
accordingly. If you need to clone the cassette into a plasmid, you can use the product as template for 
additional PCRs using the outer primers with added overhangs for restriction enzyme or Clontech In-
Fusion cloning. 
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